{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:49:40Z","timestamp":1782474580136,"version":"3.54.5"},"reference-count":34,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Pulmonology"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>New RSV prevention products show strong potential, but their success depends on wide acceptance and use. We assessed Ontario pediatricians' knowledge and attitudes about these products before their introduction to highlight opportunities and barriers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In March\u2212April 2024, Pediatricians Alliance of Ontario newsletter subscribers (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091566) were invited to complete an online survey on RSV knowledge and attitudes. Descriptive analyses with a complete\u2010case approach assessed responses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 117 responses (7% response rate), we retained 104 confirmed as from pediatricians with complete demographic data, including 81% (84\/104) general pediatricians and 19% (20\/104) subspecialists. Most worked in primary care (40%; 42\/104), community hospitals (32%; 33\/104), and urban centers (63%; 65\/104), and had \u2265\u200910 years' experience (81%; 83\/104). They had high awareness of provincial recommendations (91%; 94\/103) and knowledge of severe RSV disease risk factors (Figure 2). While 83% (82\/99) always recommended palivizumab to eligible patients, only 34% (34\/99) reported that all eligible patients always received it. Over 90% were likely to recommend nirsevimab (91%; 89\/98), but 66% (65\/98) expected to administer it. Top anticipated barriers included the introduction of a new product (69%; 25\/36) and concern for adverse effects (69%; 41\/59). The likelihood of recommending a maternal vaccine over nirsevimab was 45% (44\/98), while 44% (43\/98) were neutral.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ontario pediatricians were knowledgeable and supportive of RSV prevention products. However, they have experienced barriers with palivizumab, and they anticipated barriers with nirsevimab and the maternal RSV vaccine. As other jurisdictions look to implement new RSV prevention products, acknowledging and addressing anticipated barriers may promote acceptance and use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ppul.71696","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:56:24Z","timestamp":1781078184000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross\u2010Sectional Study"],"prefix":"10.1002","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1200-992X","authenticated-orcid":false,"given":"Adria","family":"Rose","sequence":"first","affiliation":[{"name":"Child Health Evaluative Sciences, SickKids Research Institute The Hospital for Sick Children Toronto Ontario Canada"},{"name":"Centre for Global Child Health The Hospital for Sick Children Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7151-573X","authenticated-orcid":false,"given":"Rohini R.","family":"Datta","sequence":"additional","affiliation":[{"name":"Child Health Evaluative Sciences, SickKids Research Institute The Hospital for Sick Children Toronto Ontario Canada"},{"name":"Centre for Global Child Health The Hospital for Sick Children Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3586-0612","authenticated-orcid":false,"given":"Costanza","family":"Di Chiara","sequence":"additional","affiliation":[{"name":"Centre for Global Child Health The Hospital for Sick Children Toronto Ontario Canada"},{"name":"Division of Infectious Diseases, The Department of Pediatrics The Hospital for Sick Children Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-6877","authenticated-orcid":false,"given":"Pierre\u2010Philippe","family":"Pich\u00e9\u2010Renaud","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Department of Pediatrics The Hospital for Sick Children Toronto Ontario Canada"},{"name":"Temerty Faculty of Medicine University of Toronto Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9809-0822","authenticated-orcid":false,"given":"Shaun K.","family":"Morris","sequence":"additional","affiliation":[{"name":"Child Health Evaluative Sciences, SickKids Research Institute The Hospital for Sick Children Toronto Ontario Canada"},{"name":"Centre for Global Child Health The Hospital for Sick Children Toronto Ontario Canada"},{"name":"Division of Infectious Diseases, The Department of Pediatrics The Hospital for Sick Children Toronto Ontario Canada"},{"name":"Temerty Faculty of Medicine University of Toronto Toronto Ontario Canada"},{"name":"Dalla Lana School of Public Health University of Toronto Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.36863"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piad045"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01142-w"},{"key":"e_1_2_13_5_1","first-page":"1","article-title":"Statement on the Recommended Use of Monoclonal Anti\u2010RSV Antibody (Palivizumab)","volume":"29","author":"I. National Advisory Committee on Immunization","year":"2003","journal-title":"Canada Communicable Disease Report = Releve Des Maladies Transmissibles Au Canada"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013757.pub2"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.12.24313545"},{"key":"e_1_2_13_8_1","unstructured":"Public Health Agency of Canada. Chapter 4: Canadian Immunization Guide. Respiratory Syncytial Virus (RSV) Vaccines: Canadian Immunization Guide. Government of Canada. 2024.https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/respiratory-syncytial-virus.html."},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913556"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00215-9"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216480"},{"key":"e_1_2_13_12_1","unstructured":"Ontario Ministry of Health. Respiratory Syncytial Virus (RSV) prevention programs. 2024.https:\/\/www.ontario.ca\/page\/respiratory-syncytial-virus-rsv-prevention-programs."},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2429236"},{"key":"e_1_2_13_14_1","unstructured":"Behavioural and Social Drivers of Vaccination. Tools and Practical Guidance for Achieving High Uptake 1st ed World Health Organization. 2022."},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.09.046"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1101524"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9070713"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10865-022-00296-4"},{"key":"e_1_2_13_19_1","unstructured":"Statement on the Prevention of Respiratory Syncytial Virus (RSV) Disease in Infants. [Cat. No.: HP40\u2010355\/1\u20102024E\u2010PDF] Public Health Agency of Canada = Agence de la sant\u00e9 publique du Canada. 2024.https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/publications\/vaccines-immunization\/national-advisory-committee-immunization-statement-prevention-respiratory-syncytial-virus-disease-infants\/naci-statement-2024-05-17.pdf."},{"key":"e_1_2_13_20_1","unstructured":"About the Pediatricians Alliance of Ontario (PAO). 2024 accessed April 17 2024 https:\/\/pedsallianceontario.ca\/about\/."},{"key":"e_1_2_13_21_1","unstructured":"Ontario Ministry of Health. Respiratory Syncytial Virus Prophylaxis for High\u2010Risk Infants Program Reference Manual 2023 https:\/\/files.ontario.ca\/moh-rsv-reference-manual-en-2023.pdf."},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(25)00093-8"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-01021-2"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-024-01593-1"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.22.25328182"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.24953\/turkjpediatr.2025.5528"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2341505"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127062"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.126818"},{"key":"e_1_2_13_30_1","unstructured":"J.Man H.Wong E.Castillo et al. SOGC Statement on RSV Immunization to Prevent Infant RSV Infection 2024 https:\/\/www.sogc.org\/common\/Uploaded%20files\/Position%20Statements\/SOGC%20Statement%20RSV_07182024_EN.pdf."},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.240780"},{"key":"e_1_2_13_32_1","unstructured":"Government of Ontario. Ontario Enhancing Protections for More People Throughout Fall Respiratory Illness Season [News Release] accessed August 9 2024 https:\/\/news.ontario.ca\/en\/release\/1004861\/ontario-enhancing-protections-for-more-people-throughout-fall-respiratory-illness-season."},{"key":"e_1_2_13_33_1","unstructured":"Quebec (QC). R\u00e9gie de l'assurance Maladie Du Qu\u00e9bec. Drug Formulary May 23 2024. Liste Des Medicaments. R\u00e9gis de l'assurance Maladie: Nirsevimab. 2024 accessed May 27 2024 https:\/\/www.ramq.gouv.qc.ca\/sites\/default\/files\/documents\/non_indexes\/liste_med_etab_2024-05-23_fr.pdf."},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12040383"},{"key":"e_1_2_13_35_1","unstructured":"Infant and High\u2010risk Children Respiratory Syncytial Virus (RSV) Prevention Program Guidance for Health Care Providers\u2010 Beyfortus (Nirsevimab). Ontario Ministry of Health. 2024.https:\/\/www.ontario.ca\/files\/2024-10\/moh-infant-high-risk-children-rsv-beyfortus-guidance-hcp-en-2024-10-17.pdf."}],"container-title":["Pediatric Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.71696","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ppul.71696","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.71696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:30:41Z","timestamp":1782473441000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ppul.71696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/ppul.71696"],"URL":"https:\/\/doi.org\/10.1002\/ppul.71696","archive":["Portico"],"relation":{},"ISSN":["8755-6863","1099-0496"],"issn-type":[{"value":"8755-6863","type":"print"},{"value":"1099-0496","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71696"}}